Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Strong, Lightweight and Indestructible Marble (SLIM)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Nanotechnologies
Action type: SME instrument
Countries involved: Italy
Call: Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-11-01
End date: 2017-02-28
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

BUDRI is an Italian company specialized in the execution of large scale luxury marble project for clients worldwide. Marble has been used as a construction material since classical times (Ancient Rome and Greece) due to its beauty, strength and durability. In recent times, marble is still highly valued as a construction material because although new modern materials have come up, marble is still far superior in terms of durability (average marble lifetime is 50 years compared to vinyl/hardwood at 10 years) and aesthetic characteristics. BUDRI have identified a business opportunity for strong, lightweight and indestructible marble (SLIM) for usage in a number of existing and emerging markets. With our unique production methods, we can produce marble of width of 1 mm and upon layering with composite materials and resins can produce flexible and strong natural stone with a 90% reduction in weight. With our SLIM manufacturing processes, we can eliminate up to 90% of the weight compared to conventional marble and up 35% compared to our nearest lightweight competitor. Our SLIM material is produced from off-cuts produced during our original marble business to eliminate wastage in the natural stone industry and by using thinner slabs we can preserve global resources of natural stone for years to come. At BUDRI we have identified a number of markets which desire new advanced materials which maintain their strength and durability with a low weight penalty. Our first route to market given the scale of our current operation is in developing eyewear made from natural stone. With the current eyewear market valued at €80 billion worldwide and expected to grow to €120 billion we feel that BUDRI are uniquely placed to take advantage of the need for natural materials which maintain their strength and durability while being able to produce a pair of glasses which weight < 40g.

Keywords: marble,natural stone,durability,flexible,lightweight,eyewear,sunglasses,luxury
The function of membrane tethering in plant intercellular communication (BRIDGING)

Framework: Horizon 2020 — Excellent Science
Programme: European Research Council (ERC)
Theme: European research council
Destination: Consolidator grants
Action type: ERC actions
Panel: Cellular, Developmental and Regenerative Biology
Panel description: Structure and function of the cell, cell-cell communication, embryogenesis, tissue differentiation, organogenesis, growth, development, evolution of development, organoids, stem cells, regeneration, therapeutic approaches
Countries involved: France
Call: ERC Consolidator Grant (ERC-2017-COG, 2017)
Start date: 2018-06-01
End date: 2024-05-31
Duration (months): 72.0
Total project cost (EUR): 1999840.0
EU funding (EUR): 1999840.0
Participants: 1
Project status: SIGNED

Intercellular communication is critical for multicellularity. It coordinates the activities within individual cells to support the function of an organism as a whole. Plants have developed remarkable cellular machines -the Plasmodesmata (PD) pores- which interconnect every single cell within the plant body, establishing direct membrane and cytoplasmic continuity, a situation unique to plants. PD are indispensable for plant life. They control the flux of molecules between cells and are decisive for development, environmental adaptation and defence signalling. However, how PD integrate signalling to coordinate responses at a multicellular level remains unclear. A striking feature of PD organisation, setting them apart from animal cell junctions, is a strand of endoplasmic reticulum (ER) running through the pore, tethered extremely tight (~10nm) to the plasma membrane (PM) by unidentified “spokes”. To date, the function of ER-PM contacts at PD remains a complete enigma. We don’t know how and why the two organelles come together at PD cellular junctions. I recently proposed that ER-PM tethering is in fact central to PD function. In this project I will investigate the question of how integrated cellular responses benefit from organelle cross-talk at PD. The project integrates proteomic/bioinformatic approaches, biophysical/modelling methods and ultra-high resolution 3D imaging into molecular cell biology of plant cell-to-cell communication and will, for the first time, directly address the mechanism and function of ER-PM contacts at PD. We will pursue three complementary objectives to attain our goal: 1) Identify the mechanisms of PD membrane-tethering at the molecular level 2) Elucidate the dynamics and 3D architecture of ER-PM contact sites at PD 3) Uncover the function of ER-PM apposition for plant intercellular communication. Overall, the project will pioneer a radically new perspective on PD-mediated cell-to-cell communication, a fundamental aspect of plant biology

Keywords: plasmodesmata,intercellular communication,membrane contact sites
High-tech commercial-off the-self electronics low-cost qualified for space (Space-COTS)

Framework: Horizon 2020 — Industrial Leadership
Programme: Space
Action type: SME instrument
Countries involved: Germany
Call: SME Instrument (H2020-SMEINST-1-2014, 2014)
Start date: 2015-03-01
End date: 2015-08-31
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Spectrum ARC GmbH provides an innovative state-of-the-art qualification scheme (approved by the German Space Administration DLR ) for commercial-off-the-shelf (COTS) components relevant for space and harsh-environment (radiation) applications. The space electronics market is currently dominated by US-Corporations and therefore underlies the restrictive barriers of international traffic in arms regulation (ITAR) , retarding the space industry growth and raising their cost significantly. We’ll offer so called Space-COTS by qualifying (testing) COTS from specific manufactures in different quality levels. This will enable space missions to have access to highly efficient, compact and light-weight new generation technologies at a lower price. Low-cost Space-COTS let us introduce high reliable electronic products not only for space but also for extreme-environment applications on earth, e.g. radioactive environs (power plants, research labs, nuclear medicine, etc.), hot (deserts) and cold (Antarctic) places. As technology demonstrator we’ll build a reliable and modular platform (box) consisting of a control and a removable sensor unit to be used in different environments as a Remote Monitoring System (RMS). Europe’s mission of advancing non-dependent and competitive technologies in the space sector is fully supported by this project.

Keywords: space cots,qualification,low cost eee,high reliable,itar,radiation test,radiation hardening,escc 22900 25100,cmos,bipolar
Oscillations in Basal Ganglia Disorders (OSCBAGDIS)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Spain
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2019-02-14
End date: 2021-02-13
Duration (months): 24.0
Total project cost (EUR): 170121.6
EU funding (EUR): 170121.6
Participants: 1
Project status: CLOSED

Basal ganglia is a brain structure, whose dysfunction is tightly tied with a variety of severe neurological diseases, including the widespread Parkinson’s and more rare Huntington’s diseases. Despite many efforts, current treatments for Parkinson's disease have many serious drawbacks and for Huntington’s disease barely exist. Basal ganglia play an important role in motor control and motor learning, which are both faulty in the diseases. A complete understanding of basal ganglia is still lacking though a better understanding of it is required to understand the diseases better. A distinctive feature of basal ganglia is oscillatory activity, that correlates with movement execution in different ways for different frequencies. The oscillations patterns are known to change in pathological conditions. E.g., an increase in beta-band oscillations power starts to occur in Parkinson's disease. It appears that direct high frequency stimulation of basal ganglia output structures removes some of the most important Parkinson's and Huntington's diseases symptoms. The mechanism of action of this deep brain stimulation technique is not well understood, but it is believed to act by interfering with anomalous oscillations. "How exactly basal ganglia oscillations are related to the diseases?" is an important long-standing question, that requires a system-level approach to be answered. The project aims at the development of a detailed basal ganglia system-level computational model, constrained by experimental data and coupled to a movement system. Use of analytical and numerical approaches and close interaction with experimental neuroscientists during the model development will make it provide a coherent explanation of many basal ganglia-related behaviors in healthy and pathological brains and answer the question above, in particular. Moreover, the model simulations will also give insights into new treatment/diagnostics strategies for basal ganglia-related neurological diseases.

Keywords: parkinson s disease,basal ganglia,motor learning,huntington s disease,levodopa,deep brain stimulation,neural oscillations,tremor,reinforcement learning,mathematical modelling
A General Strategy for the Generation and Use of Oxygen Centered Radicals in Organic Synthesis (ORO)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: United Kingdom
Call: Individual Fellowships (H2020-MSCA-IF-2017, 2017)
Start date: 2018-09-01
End date: 2020-08-31
Duration (months): 24.0
Total project cost (EUR): 195454.8
EU funding (EUR): 195454.8
Participants: 1
Project status: CLOSED

Oxygen-containing molecules are widespread as medicines, agrochemicals, organic materials, perfumes and dyes. Their preparation could be greatly facilitated by implementing oxygen-radicals, which are a class of very versatile synthetic intermediates. However, to date, difficulties associated to their generation have severely limited their use and exploitation in synthetic settings. Here we propose the development of two conceptually novel and general ways to prepare oxygen-radicals using visible-light. These processes will capitalize on recent developments in the host group that has disclosed two novel organocatalytic ways for the generation of nitrogen-radicals. This proposal seeks to substantially expand this photochemical approach by developing unprecedented methods for the generation and use of oxygen-radical. The power of this approach will be demonstrated by fast generation of 3D molecules containing multiple atoms of oxygen. These methods will be then integrated with other reaction platforms that, taking advantage of visible-light as source of energy, will engage the oxygen-radical in new reactivity modes, to allow novel and powerful multicomponent oxo-functionalization reactions. Furthermore, we will harness this activation modes to enable the direct oxygenation of aromatic compounds in a single step without the use of transition metal catalysts. Through the use of this strategy, the rapid construction of many relevant and complex oxygenated molecules will be possible. The development of such an innovative and ambitious project at the University of Manchester will be facilitated by generating, transferring, sharing and disseminating knowledge, and will enhance my career development following the training plan envisioned.

Keywords: oxygen radicals,visible light,photoredox catalysis,single electron transfer,electron donor acceptor complexes,oxygen heterocycle
Deciphering the fungus-host-microbiota interplay to improve the management of fungal infections (FunHoMic)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Innovative Training Networks (ITN)-European Training Networks
Action type: Marie Skłodowska-Curie actions
Panel: Life Sciences
Countries involved: Germany,Spain,Switzerland,Belgium,France,France,France,France,Netherlands,Netherlands,United Kingdom,United Kingdom
Call: Innovative Training Networks (H2020-MSCA-ITN-2018, 2018)
Start date: 2019-01-01
End date: 2023-06-30
Duration (months): 54.0
Total project cost (EUR): 3530871.36
EU funding (EUR): 3530871.36
Participants: 20
Project status: SIGNED

Fungal infections have a major impact on human health, infecting about 2 billion people and killing more people each year than malaria or breast cancer. In particular, Candida species impose a high clinical and economic burden upon the European population. They frequently cause fatal hospital-acquired bloodstream infections. They also cause oral thrush and vaginitis. Most women have suffered an episode of vulvovaginal candidiasis, with ~8% enduring recurrent infections. The initiation and severity of a Candida infection depends on an intricate interplay between the infecting fungal strain and the individual’s immune status and microbiota, all of which can display significant variability. Therefore, for the first time, FunHoMic integrates experts in fungal pathogenesis, immunology, microbial ecology and ‘omics technologies to train 13 Early Stage Researchers (ESRs) who will define and exploit this Fungal-Host-Microbiota interplay to identify novel biomarkers (fungal or host genetic polymorphisms, microbiota profiles, metabolites or immune markers) for the stratification of a patient’s risk of serious fungal infection. This will pave the way for precision medicine in patient management through preventive or therapeutic interventions using antifungals, immune modulators or Live Biotherapeutic Products (LBPs). FunHoMic ESRs will gain broad interdisciplinary skills plus a translational mindset through our integrated, inter-sectoral training program. This will allow Europe to remain at the forefront of translational research in the field of medical mycology. To achieve this vision FunHoMic unites academic partners from France, Germany, The Netherlands, Switzerland, Spain and UK, a French Technology Research Institute with cutting-edge ‘omics technology platforms and three SMEs from The Netherlands, Belgium and France that bring unrivalled organ-on-chip and gastro-intestinal tract simulation technologies and expertise in the development and exploitation of innovative LBPs.

Keywords: molecular medical mycology,candida,microbiota,omics technologies,immunology,fungal infections,ex vivo infection models,animal models
The best drug discovery platform (Ultimate)

Framework: Horizon 2020 — Industrial Leadership
Programme: Nanotechnologies, Advanced Materials, Advanced Manufacturing and Processing, and Biotechnology
Theme: Nanotechnologies
Action type: SME instrument
Countries involved: Hungary
Call: Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs (H2020-SMEINST-1-2016-2017, 2016)
Start date: 2016-06-01
End date: 2016-11-30
Duration (months): 6.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

Mcule.com aims to provide the best web-based drug discovery platform for pharmaceutical researchers (big companies, contract research organisations and academics). We aim to create an easily searchable chemical database of 500 million purchasable compounds, the Ultimate database. The Ultimate database would be primarily based on virtual (not yet synthesized, but predicted to be synthesizable) compounds. Such a large chemical space would present a major advantage for pharma and biotech companies by increasing their chances to effectively identify novel compounds, reducing their costs and time losses. This development will increase our market share and promote our growth.

Keywords: drug discovery,computational chemistry,pharmaceutical industry,molecular database
A novel Holistic Automated Analytics System for IT infrastructure management that proactively identifies and prevent IT operational threats. (CorreAssess)

Framework: Horizon 2020 — Societal Challenges
Programme: Secure societies - protecting freedom and security of Europe and its citizens
Action type: SME instrument
Countries involved: Israel
Call: Engaging SMEs in security research and development (H2020-SMEINST-1-2016-2017, 2017)
Start date: 2017-11-01
End date: 2018-02-28
Duration (months): 4.0
Total project cost (EUR): 71429.0
EU funding (EUR): 50000.0
Participants: 1
Project status: CLOSED

A typical Data Centre is comprised of multiple hardware and software components from different manufacturers, each with their own management tools, silo dashboard and limited sharing capabilities of business operations control data. This problem seems to get worse as IT-based companies are moving towards dynamic and complex virtualized and cloud environments. Moreover, when working on system´s safety, disrupting even one element of this fragile infrastructure runs the risk of affecting other systems, causing serious damage to the business. The average reported incident length is of 86 minutes, resulting in an average cost per incident of about $690,200. CorreAssess™ is an innovative game-changing Data Center Optimization Management system for business IT leaders that empowers companies with a complete visibility and control on all their IT infrastructure, through accurate detailed analytics insights delivered on a daily basis. It helps to generate valuable information for wise usage of IT infrastructure investments, resource allocation efficiency, IT alignment to defined SLAs, compliance, service availability, data recovery risks and easier cloud migration, alerting in advance before threats impact the company business. With CorreAssess™ companies will be able to reduce up to 25% the infrastructure investment costs and prevent risks of business failure by improving business continuity up to 80%. So far, €2M million have been raised and invested into the development and testing of the system to ensure its robustness and efficiency and move into the next stages of commercialisation. Within the overall project, we intend to finalise systems engineering and conduct a wide pilot trial within Europe. Current IP portfolio will be expanded to EU. The proposed work in Phase 1 of the SME instrument fits into our overall plan to reach the market by contributing the financial resources needed to plan a fast sound wider deployment of CorreAssess™ and its market uptake.

Keywords: itoa,management,risks,server,providers,operation,analytics,compliance,infrastructure
BMX-targeted ligand-drug conjugates for prostate cancer therapy (LDC4PCaTher)

Framework: Horizon 2020 — Excellent Science
Programme: Marie-Sklodowska-Curie Actions
Theme: Marie Skłodowska-Curie
Destination: Individual Fellowships (IF)-Standard European Fellowships
Action type: Marie Skłodowska-Curie actions
Panel: Chemistry
Countries involved: Portugal
Call: Marie Skłodowska-Curie Individual Fellowships (IF-EF) (H2020-MSCA-IF-2015, 2015)
Start date: 2016-11-01
End date: 2019-01-12
Duration (months): 24.0
Total project cost (EUR): 160635.6
EU funding (EUR): 160635.6
Participants: 1
Project status: CLOSED

Standard of care strategies for the treatment of cancer still relies heavily on non-specific radiation and chemotherapy. These treatments are commonly associated with severe toxicities and in many cases only offer limited benefit for the patient. The targeted delivery of radionuclides, cytotoxic drugs and pro-inflammatory cytokines into malignant tissue, on the other hand, can markedly improve the therapeutic index and overall efficacy of such substances. Whilst monoclonal antibodies are the most widely used delivery vehicles to date, low molecular weight targeted agents are emerging as a promising alternative to antibody-based drug delivery. These ligands have negligible immunogenic risk and are easier to chemically modify enabling fine tuning of their ADME profile. As a result, it is possible to achieve a time dependent release of the cytotoxic payload at the target tissue maximizing its therapeutic efficacy while producing minimal damage to healthy cells. Most importantly, depth of tumour penetration and tumour-to-blood distribution ratio after injection should be significantly superior. We therefore propose to systematically investigate the targeting performance of bone marrow tyrosine kinase in chromosome X (BMX) ligands for the targeted delivery of cytotoxic drugs into BMX-overexpressing tumours, namely prostate cancer. This project aims at (1) demonstrate that a BMX ligand can selectively accumulate in BMX-overexpressing cancers; (2) developing a general chemical approach for building safe ligand-drug conjugates (LDCs); and (3) when site-specifically conjugated to cytotoxic drug, this novel LDC is highly effective for the treatment of prostate cancer. This project is expected to explore new avenues for drug delivery systems since the concepts here proposed go beyond prostate cancer therapy as they can be applicable to any ligand that interferes with up-regulated disease-related pathways.

Keywords: ligand drug conjugates,targeted drug delivery,covalent kinase inhibitors,prostate cancer